Cot siRNA (h) from Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

(1) Therapeutic Potential of Tpl2 (Tumor Progression Locus 2) Inhibition on Diabetic Vasculopathy Through the Blockage of the Inflammasome ComplexArteriosclerosis, thrombosis, and vascular biologyJanuary 1, 2021Sheu WH, Lin KH, Wang JS, Lai DW, Lee WJ, Lin FY, Chen PH, Chen CH, Yeh HY, Wu SM, et al.listed in Tables 2 and 3 Transient Transfection Lipofectin (Invitrogen) was used to deliver Tpl2 siRNA (sc35095, Santa Cruz Biotechnology, CA), RAGE (receptor for advanced glycation end products) shRNA, TLR (Toll-like receptor)

(3) The protein kinase TPL2 is essential for ERK1/ERK2 activation and cytokine gene expression in airway epithelial cells exposed to pathogen-associated molecular patterns (PAMPs)PloS oneJanuary 1, 2013Martel G, Bérubé J, Rousseau S.stimulation with agonists and/or inhibitors. Silencing Experiments RAF1 siRNA (sc-29462), TPL2 siRNA (sc-35095) and siRNA transection reagent (sc-29528) were bought from Santa Cruz Biotechnology. BEAS-2B AECs were

Cot siRNA (h)